Inactive Instrument

Highlights Cancer Genetics, Inc.

Equities

CGIX

US13739U2033

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cancer Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Cancer Genetics and StemoniX Announce Merger Closing	21-03-31	GL
Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-31	CI
StemoniX Inc. completed the acquisition of Cancer Genetics, Inc. from a group of shareholders in a reverse merger transaction.	21-03-29	CI
Cancer Genetics : Secures Shareholder Nod for Proposed StemoniX Merger	21-03-25	MT
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX	21-03-25	GL
Cancer Genetics : Earnings Flash (CGIX) CANCER GENETICS Reports Q3 Revenue $1.57M	20-11-12	MT
Cancer Genetics : Earnings Flash (CGIX) CANCER GENETICS Reports Q3 Revenue $1.57M	20-11-12	MT
Cancer Genetics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI
Cancer Genetics, Inc. and StemoniX Inc. Announce Joint Proof of Concept Program	20-09-03	CI
CANCER GENETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cancer Genetics, Inc. - CGIX	20-08-26	BU
StemoniX Inc. entered into a definitive merger agreement to acquire Cancer Genetics, Inc. from a group of shareholders for $55.1 million in a reverse merger transaction.	20-08-23	CI
Cancer Genetics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-13	CI
Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-05-29	CI
Cancer Genetics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-19	CI
Cancer Genetics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-19	CI
Interpace Diagnostics Group, Inc. acquired BioPharma Business of Cancer Genetics, Inc. for $26.5 million.	19-07-14	CI
Siparadigm, LLC acquired Clinical Laboratory Business of Cancer Genetics, Inc. for $0.82 million.	19-07-08	CI
Cancer Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cancer Genetics, Inc.

Equities

CGIX

US13739U2033

Highlights

Filters